Every 10-Q that OS Therapies Incorporated (OSTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OSTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSTX filings page.
OS Therapies Incorporated is a clinical-stage biotech developing OST-HER2 for osteosarcoma and other HER2-positive tumors. For the six months ended June 30, 2026, it reported a net loss of $19.0 million, driven mainly by a sharp increase in research and development expenses to $13.4 million and consulting fees tied to regulatory preparations.
Total assets were $9.9 million, including a new $3.1 million VAT receivable, while cash was only $205,035 and stockholders’ deficit widened to $(11.9) million. Operating activities used $10.1 million of cash, largely offset by $10.0 million from warrant exercises, convertible notes and an April 2026 registered direct equity offering that raised about $4.8 million net. Management concluded that low cash, ongoing losses and an expected $24.0 million in vendor and regulatory costs raise substantial doubt about the company’s ability to continue as a going concern, despite an August 10, 2026 secured note financing providing approximately $4.7 million net and access to additional borrowings.
Clinically, the Phase IIb trial of OST-HER2 in recurrent osteosarcoma met its primary endpoint and showed statistically significant overall-survival benefits versus historical controls at two and 2.5 years, supporting planned BLA and European conditional MAA submissions.
OS Therapies Incorporated reported a Q1 2026 net loss of $10.4 million, significantly higher than the $3.9 million loss a year earlier, driven mainly by a sharp increase in research and development spending to $7.4 million.
Cash was $0.9 million at March 31, 2026, against current liabilities of $17.0 million and total stockholders’ deficit of $10.8 million. Management concluded these conditions raise substantial doubt about the company’s ability to continue as a going concern, despite raising new capital through warrant exercises, convertible notes and an April 2026 registered direct offering.
OS Therapies (OSTX) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $6.9 million for the quarter and $15.3 million year‑to‑date, driven by higher research and development ($7.6 million YTD) and general and administrative expenses ($9.2 million YTD). Cash was $1.88 million, and management stated these conditions raise “substantial doubt” about the company’s ability to continue as a going concern.
Total assets rose to $9.0 million, reflecting the April acquisition of HER2 immuno‑oncology assets from Ayala, recorded at a fair value of $6.86 million, largely paid in common stock. The company recognized $236 thousand of amortization on these intangibles year‑to‑date. Stockholders’ equity improved to $3.64 million from a deficit at year‑end 2024, aided by conversions of preferred stock and warrant activity.
Operating cash burn was $10.5 million YTD, partly offset by $7.3 million in financing cash inflows, including warrant exercises and a preferred stock raise. The warrant liability declined to $0 with a $1.42 million favorable fair value change. Shares outstanding were 35,214,352 as of November 14, 2025.
OS Therapies Incorporated (OSTX) reported interim financials showing material financing activity and a continued need for capital. The company completed Unit financings that generated $6,050,000 and $1,053,000 in gross proceeds allocated between Series A Preferred Stock and attached warrants. Convertible notes converted at the company IPO on August 2, 2024, eliminating related redemption liabilities. Warrant liability of $1,971,975 at December 31, 2024 was reclassified to equity by April 9, 2025, leaving $0 warrant liability at June 30, 2025. Common shares outstanding increased to 29,918,194 at June 30, 2025 from 20,869,908 at December 31, 2024. Cash balances included $2,056,885 at Chase and $728,988 at SVB as of June 30, 2025. The company states its ability to continue operations is dependent on obtaining additional capital. Research and development expense recorded was $0 for the six months ended June 30, 2025 versus $86,687 in the prior-year period. The company acquired HER2-related assets with cash and stock consideration and modified license and royalty arrangements, including license commencement payments and milestone schedules.